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Abstract
Background: Human Leukocyte Antigen (HLA)-E is a non-classical class I HLA molecule that can be stabilized by
ligands donated by other classical (HLA-A, -B, -C) and non-classical (HLA-G) family members. HLA-E engages a
variety of immune receptors expressed by cytotoxic T lymphocytes (CTLs), Natural killer (NK) cells and NK-CTLs. In
view of the opposing outcomes (activation or inhibition) of the different HLA-E receptors, the preferred role (if any)
of HLA-E expressed in vivo on tumor cells remains to be established.
Methods: Taking advantage of MEM-E/02, a recently characterized antibody to denatured HLA-E molecules, HLA-E
expression was assessed by immunohistochemistry on an archival collection (formalin-fixed paraffin-embedded) of
149 colorectal primary carcinoma lesions paired with their morphologically normal mucosae. Lymphoid infiltrates
were assessed for the expression of the HLA-E-specific, inhibitory, non-rearranging receptor NKG2A.
Results: High HLA-E expression did not significantly correlate with the expression of classical HLA-B and HLA-C
molecules, but it did correlate with high expression of its preferential ligand donor HLA-A. In addition, it correlated
with lymphoid cell infiltrates expressing the inhibitory NKG2A receptor, and was an independent predictor of good
prognosis, particularly in a subset of patients whose tumors express HLA-A levels resembling those of their paired
normal counterparts (HLA-A). Thus, combination phenotypes (HLA-E
lo-int/HLA-AE and HLA-E
hi/HLA-AE) of classical
and non-classical class I HLA molecules mark two graded levels of good prognosis.
Conclusions: These results suggest that HLA-E favors activating immune responses to colorectal carcinoma. They
also provide evidence in humans that tumor cells entertain extensive negotiation with the immune system until a
compromise between recognition and escape is reached. It is implied that this process occurs stepwise, as
predicted by the widely accepted ‘immunoediting’ model.
Background
Human Leukocyte Antigen (HLA)-E is a cell surface,
non-classical Major Histocompatibility class I molecule
recognized by immune receptors expressed by cytotoxic
T lymphocytes (CTLs), Natural Killer (NK) cells, and the
more recently described subset of NK-CTLs. These
receptors are either inhibitory or activating [1-3].
Inhibition, on the one hand, results from the engage-
ment of the NKG2A receptor with HLA-E heavy chains
that have been stabilized upon heterotrimeric assembly
with their light chain subunit, called b2-microglobulin
(b2m), and peptide ligands derived from the signal
sequences of ‘permissive’ class I heavy chains, both classi-
cal (HLA-A, -B, -C) and non-classical (HLA-G). Activa-
tion, on the other hand, results from: (a) the competitive
relief of NKG2A-mediated inhibition upon HLA-E
assembly with peptides from donor proteins other than
HLA class I; (b) the direct engagement of the activating
NKG2C receptor isoform; and (c) antigen-specific recog-
nition through the T cell receptor (TcR) expressed by
NK-CTLs [1-4]. Balancing and integration of opposing
signals (often dubbed activation-inhibition) is not unique
of HLA-E, but is indeed widely adopted to control cyto-
toxic responses and regulate complex immune networks.
Thus, HLA-E may provide key information to understand
how virus-infected [5] and tumor cells walk the thin line
between immune surveillance and immune evasion.
* Correspondence: giacomini@ifo.it
2Laboratory of Immunology, Regina Elena National Cancer Institute, Via delle
Messi d’Oro 156, 00158 Rome, Italy
Full list of author information is available at the end of the article
Benevolo et al. Journal of Translational Medicine 2011, 9:184
http://www.translational-medicine.com/content/9/1/184
© 2011 Benevolo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.HLA-A, -B, -C down-regulation has been viewed as a
major subterfuge to deceive T cells [6] for some time
now, but it is unlikely to provide a comprehensive expla-
nation of immune evasion, since it impairs ligand dona-
tion to HLA-E and the direct engagement of inhibitory
NK receptors [1,7-9]. Accordingly, several immunohisto-
chemical studies failed to confirm an association between
HLA-A, -B, - C loss and poor prognosis [10-12], and our
own studies were consistent with activation-inhibition
models [13-16]. We showed that early-passage mela-
noma, breast carcinoma, and lung carcinoma cells, like
virus-infected cells, avoid both extremes of overly low or
high HLA class I expression, which would expose them
to lysis by NK and CTLs, respectively. Similar ‘low pro-
file’ HLA phenotypes were also observed in vivo, in color-
ectal carcinoma lesions, and were associated with a
favorable prognosis, whereas extreme down-and up-regu-
lation with respect to the normal autologous mucosa
were rare and associated with a poor prognosis, particu-
larly when involving the HLA-A locus [16]. Possibly,
these altered HLA phenotypes mark tumor cells refrac-
tory to immune elimination.
In an effort to characterize monoclonal antibodies
(mAbs) to HLA-E, we found that MEM-E/02 binds a lin-
ear epitope highly restricted to the HLA-E polypeptide
and fully available upon denaturation [17]. Using MEM-
E/02, we recently observed that HLA-E is constitutively
co-expressed with HLA-A, -B, -C molecules in a fraction
of neoplastic tissues and on the surface of most cultured
tumor cell lines. In these conditions, HLA-E is functional
[18]. In the present report, we describe the use of MEM-
E/02 on archival collections of formalin-fixed/paraffin-
embedded colorectal adenocarcinoma tissues and their
paired, morphologically normal mucosae. We found that
overall HLA-E expression is a significant prognosticator,
and in combination with HLA-A expression and the pre-
sence of NKG2A infiltrating lymphoid cells provides a
clue to understand tumor immune surveillance in vivo.
Methods
Patients and histological specimens
Patients (149 cases, 71 men and 78 women, median age
64, range 34-90 years) were radically resected for primary
colorectal adenocarcinoma between 1988 and 2000.
Pathological staging [19], performed according to the
American Joint Committee on Cancer (AJCC)/Interna-
tional Union Against Cancer (UICC), identified 98 and
51 tumors at stages II and III, respectively. The latter
were treated by adjuvant chemotherapy. According to the
WHO classification, well (G1), moderately (G2), and
poorly (G3) differentiated tumors were 10, 114, and 25,
respectively. T2, T3 and T4 tumors were 26, 63, and 60,
respectively. The present archival tissue collection largely
overlaps (n = 126) with that previously described [16].
Uninvolved mucosal tissues were obtained from the same
tissue block as the tumor lesion in 108 cases, and from a
distinct tissue block in 41 cases. No patients were lost to
clinical follow-up (continuously updated), and the med-
ian follow-up was 71.0 (range 3.0 - 175.1) months, with
45 relapses and 37 deaths due to cancer-related causes.
This study was approved by the Ethical Committee.
Antibodies and Immunohistochemistry
MEM-E/02 is the only available mAb to HLA-E with an
extensive biochemical characterization. It binds a linear
epitope present on HLA-E but not HLA-A, -B, -C, -F or
- Gh e a v yc h a i n s[ 1 7 ] .H C A 2b i n d sa l lt h ed e n a t u r e d
HLA-A alleles except A24, and crossreacts with the rare
HLA-B73 allele, HLA-G, HLA-E and HLA-F [20,21].
However, HLA-E and HLA-F bind weakly and almost
exclusively under native conditions [21], and HLA-G
accounts for less than 5% of the total HCA2 reactivity in
a large cell panel [15]. HC10 binds HLA-B and weakly
crossreacts with HLA-C, whereas L31 binds HLA-C and
a few crossreacting HLA-B alleles [20,22,23]. CD8 and
CD56 were identified by mAbs 1A5 and 1B6 (Novocastra,
UK), respectively. The goat polyclonal antibody N-19 to
NKG2A was from Santa Cruz (CA, USA). Sections (5-μm
thick) from routinely formalin-fixed (18-24 h) paraffin-
embedded tissue blocks were stained by Immunohisto-
chemistry (IHC). Antigen retrieval for HCA2, HC10, L31,
CD8 and CD56 staining was carried out as described
[23]. For MEM-E/02 and NKG2A staining, slides were
dewaxed, rehydrated and heated in a water bath at 96°C
for 40 minutes in EDTA (pH 8.0), followed by cooling at
room temperature. Staining was revealed by a supersensi-
tive streptavidin-biotin immunoperoxidase system (Bio-
genex, Menarini, Italy) for all antibodies. In addition,
NKG2A staining was also revealed by a Goat AP-Polymer
Kit (Biocare Medical, CA, USA). The chromogenic sub-
strate was 3,3’-diaminobenzidine for all stainings. In
addition, NKG2A staining was also revealed by Warp
Red (Biocare Medical). Preliminary specificity assess-
ments were performed on a panel of HLA-E-positive and
HLA-E-negative cell lines [17] fixed and embedded as
above. Different staining sessions included repeated
staining of an internal normalization control (a section
from a known specimen) to ensure day-to-day consis-
tency. Because weak staining was invariably associated
with the presence of negative areas, whereas strong stain-
ing tended to be homogeneous (this applies to both nor-
mal and tumor tissues), staining heterogeneity and
staining intensity were factored into a single scale
(termed ’absolute’ intensity score hereafter). The absolute
intensity score may acquire one of four possible values: 0
(undetectable or faint in <20% of the cells); 1 (faint to
weak in 20% but ≤70% of the cells); 2 (weak to moderate
in >70% of the cells); 3 (intense in>70% of the cells).
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lated an additional intensity scale (termed ’relative’ here-
after) by subtracting the absolute score of the normal
mucosa from that of its paired colon carcinoma speci-
men. Subtraction of two series of scores, each graded on
a four-digit scale, resulted in the assignment of one of 7
possible algebraic values (-3, -2, -1, 0, +1, +2, +3) to each
normal-neoplastic pair. Intermediate (-1, 0,a n d+1)a n d
extreme (-3, -2, +2,a n d+3) relative scores identify pairs
in which the tumor is similar to and deviates from,
respectively, its normal paired mucosa. CD3, CD56 and
NKG2A infiltrates were assessed in six randomly chosen
high power fields (HPF, ×400), and expressed as either
the percentage of positive cells in the total infiltrate, or
the average number of positive cells in each HPF.
Statistical analysis
Descriptive statistics were used to summarize pertinent
study information. The Spearman rho correlation was
used to determine relationships between parameters. The
Hazard risk and the confidence limits were estimated for
each variable using the Cox univariate model. Signifi-
cance was defined at the p < 0.05 level. A multivariate
Cox proportional hazard model was also developed using
stepwise regression (forward selection) by selecting those
predictive variables that were significant upon univariate
analysis. Enter limit and remove limit were p =0 . 1 0a n d
p = 0.15 respectively. Survival was calculated by the
Kaplan-Meier product-limit method from the date of sur-
gery until the time of death (overall survival; OS), relapse
(disease-free survival; DFS), or last visit (OS and DFS),
whichever applicable. The log-rank test was used to
assess differences between subgroups. Significance was
defined at the p < 0.05 level. Statistical analysis was car-
ried out by the SPSS v. 13.0 (SPSS, Milan, Italy) software.
Optimal cut-offs of NKG2A immunoreactivity defining
two groups of patients with significantly different MEM-
E/02 intensity scores were found using the Receiver
Operating Characteristic (ROC) curve analysis.
HLA-A, -B, -C typing
Genomic DNAs were extracted from the available frozen
tumor tissue samples (n = 29), and typed for HLA-A, -B,
and -C using sequence-specific primers (Olerup-SSP,
Genovision, Vienna, Austria).
Results
Analysis of MEM-E/02 immunoreactivity in colorectal
carcinomas and paired mucosa specimens
Colorectal carcinomas from stage II/III patients (n = 149),
each paired with morphologically normal colonic mucosa
f r o mt h es a m ep a t i e n t ,w e r es t a i n e db yi m m u n o h i s t o -
chemistry with the HLA-E-specific MEM-E/02 antibody.
Representative examples of staining grades (recorded as
absolute scores, see Materials and Methods) are provided
in Figure 1A-C. HLA-E was detected in nearly all the spe-
cimens, approximately half of which displayed the highest
absolute score of 3. High absolute scores were most fre-
quent also with HCA2 (to HLA-A), HC10 (to HLA-B) and
L31 (to HLA-C), as shown in Additional file 1, Fig. S1A.
Similar results were obtained by plotting the staining
intensities of the normal mucosae (not shown). Thus,
HLA-E is expressed in essentially all normal and neoplas-
tic colonic tissues, often at high levels.
Next, we calculated the seven-digit relative intensity
scores (see Materials and Methods) of paired immunohis-
tochemical determinations. Representative results (Addi-
tional file 1, Fig. S1B) demonstrate that tumors resembling
their normal paired mucosa (relative scores: +1, 0, and -1)
were far more numerous than tumors undergoing consis-
tent up-regulation or down-regulation (relative scores: -2,
-3 and +2, +3), a finding that applies to all the tested HLA
class I molecules: HLA-E, HLA-A, HLA-B and HLA-C.
Finally, flow cytometry of 3 representative colorectal car-
cinoma cell lines provided evidence that at least some of
the denatured HLA-A and HLA-E molecules detected by
HCA2 and MEM-E/02 on archival tissues derive from
native molecules that are co-expressed on the surface of
live cells (Additional file 1, Fig. S2).
Co-expression of HLA-E and permissive class I alleles
It has been shown that signal sequence-derived peptides
from permissive alleles (most HLA-A and some HLA-C)
carry methionine at P2, whereas peptides from non-per-
missive alleles (most HLA-B) carry threonine [24,25]. On
this basis, absolute HLA-E levels are expected to correlate
with (a) the levels of co-expressed products from at least
some HLA-A, -B, and -C loci, and (b) the number of per-
missive alleles carried at the DNA level. To verify predic-
tion (a), the staining intensities of MEM-E/02 (to HLA-E)
were correlated with the staining intensities of HCA2,
HC10, and L31 (preferentially reactive with HLA-A, HLA-
B and HLA-C, respectively) in the 149 tumor specimens.
A significant (Table 1, p = 0.01) correlation was detected
between HLA-E and HLA-A, but not HLA-B or HLA-C.
To verify prediction (b), 29 high-quality genomic DNAs
(required for reliable allele-specific PCR) from colon carci-
noma lesions were typed for HLA-A, -B, -C. From 3 to 6
permissive alleles (alleles and signal sequences listed at
<http://hla.alleles.org/data/index.html>) were identified in
each DNA. As in the complete case collection, HLA-E and
HLA-A staining intensities did correlate also in this smal-
ler subset (Table 1, p = 0.02; also see Additional file 1, Fig.
S3A). In addition, there was a weak non-significant trend
for correlation between the number of the putative HLA-
A/-B/-C donor alleles and HLA-E staining intensity (Addi-
tional file 1, Fig. S3B). We conclude that HLA-E and at
least its preferred ligand donors (from the HLA-A locus)
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in vivo.
Association between HLA-E expression and survival
Next, univariate analysis and multivariate analysis of DFS
and OS (Cox model) were performed on the entire series
of 149 stage II/III colorectal cancer patients. In agree-
ment with our previous study [16], advanced tumor stage
and extreme up-/down-regulation of HCA2-reactive
(HLA-A) molecules (relative scores of +3, +2, -3,a n d-2)
were significant and independent predictors of both DFS
and OS (Table 2, top two lines in both sections), whereas
t h ea b s o l u t er e a c t i v i t ys c o r e so fH C A 2 ,H C 1 0a n dL 3 1
(Table 2, last three lines in both sections) as well as the
relative reactivity scores of HC10 and L31 (not shown)
were not. Contrary to HCA2, and quite surprisingly, the
relative MEM-E/02 scale did not identify any significant
prognostic category (not shown).
However, a high MEM-E/02 absolute staining intensity
score of 3 did display a significant correlation with
favorable prognosis upon both univariate analysis and
multivariate analysis (Table 2, third line from top in
both sections). Accordingly, Kaplan-Meier analysis (Fig-
ure 2A and 2B) was consistent with significantly longer
DFS and OS in patients bearing tumors with high levels
of absolute MEM-E/02 reactivity (HLA-E
hi).
Next, we investigated whether a combined evaluation
of relative HCA2 reactivity and absolute MEM-E/02
Figure 1 Immunohistochemical staining of formalin-fixed, paraffin-embedded colorectal carcinoma tissues. A-C: Representative reactivity
scores of MEM-E/02 to HLA-E (see Materials and Methods): A = 1,B=2,C=3. D: staining of lymphoid infiltrates with an antibody to the HLA-E-
specific receptor NKG2A. Magnification: 10×, 40×, 20×, and 40× respectively. Scale bar = 100 μm.
Table 1 Correlations among antibody reactivity scores
HCA2
(HLA-A)
HC10
(HLA-B)
L31
(HLA-C)
rpr p r p
MEM-E/
02
All specimens
(n = 149)
0.20 0.01 0.13 0.11 0.07 0.28
HLA-typed specimens (n
= 29)
0.42 0.02 0.08 0.69 0.13 0.51
Significant correlations boldface.
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diction. In the patients with unfavorable HCA2 pheno-
types (extreme HLA-A up-/down-regulation), absolute
HLA-E expression did not significantly associate with 5-
year DFS and OS (not shown), suggesting that ‘abnor-
mal’ HCA2 reactivity is a dominant prognostic factor,
and the influence of HLA-E in this tumor subset is neg-
ligible. In contrast (Figure 2C and 2D), among patients
bearing tumors with HLA-A levels similar to that of the
normal autologous mucosa (that are by themselves asso-
ciated with favorable prognosis), high and low/inter-
mediate HLA-E expression levels further discriminated
two numerically equivalent populations (n =4 9v s4 5 )
significantly differing in their chances of relapse and
death within 5 years.
Correlation between HLA-E expression in tumors and
NKG2A expression in lymphoid infiltrates
Sixteen lesions expressing the highest HLA-E levels
(MEM-E/02 score = 3), and 12 lesions expressing the low-
est levels (score = 1) were assessed for NKG2A (Figure
1D), CD8 and CD56 infiltrates (not shown). Up to 5% and
20% of colorectal carcinoma infiltrates were reactive with
NKG2A and CD8, respectively. In contrast, only scattered
CD56 cells (no more than 2 per microscopic field) were
detected. As shown by a representative stain of serial sec-
tions (Figure 3), the distribution of NKG2A-positive and
CD8-positive cells partly overlaps.
Upon ROC analysis there was no significant correla-
tion between CD8 infiltrate (either the extent or num-
ber of positive cells) and HLA-E expression. In
contrast, high and low levels of the HLA-E ligand in
tumor tissues correlated with high and low numbers,
respectively, of infiltrating lymphoid cells expressing its
specific receptor NKG2A (Additional file 1, Table S1;
p = 0.04).
Discussion
Although intracellular transport of HLA-E is believed to
be quite inefficient [26], colorectal carcinoma cells (like
most neoplastic cell lines) co-express on the surface
HLA-E and classical HLA class I molecules, including
HLA-A ([18] and Additional file 1, Fig. S2).
The present immunohistochemical study of colorectal
carcinoma lesions with the MEM-E/02 antibody [17]
reveals that high expression of HLA-E significantly corre-
lates with high expression of HLA-A, but not HLA-B or
HLA-C. Since HLA-E ligands donated by most HLA-B
and at least some HLA-C alleles are poorer NKG2A inhi-
bitors than those donated by HLA-A alleles [27], in vitro
Table 2 Univariate and multivariate analyses of prognostic factors for disease-free and overall survival of stage II and
III colon carcinoma patients
DISEASE-FREE SURVIVAL
Univariate Analysis Multivariate Analysis
Prognostic factors HR
1 (95% CI)
2 p value HR (95% CI) p value
Stage III vs II 2.55 (1.41-4.60) 0.002 2.77 (1.45-5.28) 0.002
HCA2 relative score (+3/+2/-3/-2 vs others) 2.50 (0.18-5.31) 0.02 2.94 (1.36-6.34) 0.006
MEM-E/02 absolute score (0/1/2 vs 3) 1.90 (1.05-3.45) 0.03 1.82 (0.96-3.45) 0.06
T (3/4 vs 1/2) 1.26 (0.56-2.82) 0.58
Grading (2/3 vs 1) 1.95 (0.47-8.04) 0.36
HCA2 absolute score (0/1 vs 2/3) 1.47 (0.77-2.79) 0.25
HC10 absolute score (2/3 vs 0/1) 2.40 (0.74-7.74) 0.14
L31 absolute score (0/1 vs 2/3) 1.36 (0.73-2. 57) 0.33
OVERALL SURVIVAL
Univariate Analysis Multivariate Analysis
Prognostic factors HR
1 (95% CI)
2 p value HR (95% CI) p value
Stage III vs II 2.78 (1.45-5.34) 0.002 2.49 (1.23-5.04) 0.01
HCA2 relative score (+3/+2/-3/-2 vs others) 3.09 (1.43-6.69) 0.004 3.55 (1.61-7.87) 0.002
MEM-E/02 absolute score (0/1/2 vs 3) 1.96 (1.01-3.81) 0.05 1.81 (0.90-3.63) 0.09
T (3/4 vs 1/2) 1.41 (0.55-3.61) 0.48
Grading (2/3 vs 1) 1.57 (0.38-6.52) 0.54
HCA2 absolute score (0/1 vs 2/3) 1.66 (0.83-3.31) 0.15
HC10 absolute score (2/3 vs 0/1) 1.91 (0.59-6.22) 0.28
L31 absolute score (0/1 vs 2/3) 1.21 (0.60-2.44) 0.61
1 HR: hazard risk
2 CI: 95% confidence interval
Significant correlations boldface
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appear to be recapitulated in vivo.
Ligand donation by permissive HLA class I alleles is a
well-known strategy to signal integrity of the so-called
antigen processing machinery, and prevent inappropriate
immune lysis upon HLA-E:NKG2A inhibition [1,2].
Consistent with HLA-E enabling active scrutiny by the
immune system (rather than immunoevasive responses),
we show herein that HLA-E
hi phenotypes are associated
with a lymphoid infiltrate (mainly CD8) enriched in the
HLA-E-specific inhibitory receptor NKG2A, and a favor-
able prognosis.
Similar to previous studies [28,29], in which the extent
of the colorectal carcinoma lymphoid infiltrate was cor-
related with a favorable prognosis, only scattered NK
cells were detected herein. However, this does not
obviously rule out a role of infiltrating NK cells in vivo.
Interestingly, we found that high HLA-E expression is
associated per se with a favorable outcome, but it is the
combination between high HLA-E (on an absolute
scale) and similar HLA-A levels in the tumor compared
t ot h en o r m a lm u c o s a( o nar e l a t i v ee x p r e s s i o ns c a l e )
that results in the precise identification of graded levels
of prognosis.
Figure 2 Kaplan-Meier survival curves of patients with colorectal carcinoma. Five-year disease-free (A) and overall (B) survival rates of 149
stage II-III colorectal cancer patients according to the MEM-E/02 (HLA-E) absolute immunohistochemical score (MEM-E/02
hi= 3; MEM-E/02
lo/int: 0,
1 and 2). Five-year disease-free (C) and overall (D) survival of stage II-III colon carcinoma patients according to the HCA2 (HLA-A) relative
immunohistochemical score (0, -1, +1 vs +2, +3, -2, -3). Patients (n = 94) with an HCA2 reactivity mimicking that seen in the normal paired
mucosa (relative scores 0, -1 and +1) were sorted into MEM-E/02
hi (absolute reactivity score = 3) and MEM-E/02
lo/int (0, 1, and 2). The percent
survival, shown in ordinate, is analytically displayed for the different groups at the end of the observation period, along with the statistical
significance (p) of the observations.
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landscape both in quantitative and qualitative terms.
Quantitatively, HLA-A identifies a wider prognostic gap
between favorable and poor outcomes. Qualitatively,
HLA-A was shown previously to be an early-stage prog-
nosticator [16], whereas HLA-E is shown herein to influ-
ence prognosis particularly within a cohort of patients
pre-selected for a favorable outcome through HLA-A
phenotyping.
The easiest interpretation of these results involves the
assignment of the observed HLA-A and HLA-E phenoty-
pic variants to the three classical phases (elimination, equi-
librium and escape; boxes n. 1, 2 and 3 in Figure 4) of the
widely accepted ‘immunoediting’ theory. This theory was
originally proposed by Dunn et al.[30] to interpret murine
models of tumor escape. We are not aware of previous
attempts to classify specific class I HLA phenotypes in the
context of stepwise immunoediting. We propose that in
the first immunoediting phase (box 1, elimination), HLA-
A
hi and HLA-A
lo phenotypes are suppressed, for instance
by anti-tumor CTL and NK cells equipped with function-
ally dominant activating and inhibitory receptors, respec-
tively. As described by us several years ago [13,14], this
results in the selection of ‘low profile’ (HLA-A phenotypes,
e.g. colorectal carcinoma cells expressing HLA-A levels
similar to those of their normal counterparts. Next, two
phenotypes arise characterized by different HLA-E levels
(box 2, immunoediting): HLA-A/HLA-E
lo/int and HLA-A/
HLA-E
hi. Low/intermediate and high HLA-E levels are
hypothesized to result: (a) the former from limited ligand
donation and HLA-E stabilization, as a result of HLA-A
hi
suppression during the previous elimination phase; (b) the
latter from HLA-A-independent events of ligand donation.
Why both might incite anti-tumor immune responses, at
two different levels, could be explained by relief of lytic
inhibition and/or triggering immune responses. There are
precedents for both. Relief of inhibition by competitive
binding of non-HLA-derived ligands is known to favor NK
lysis [4]. Direct triggering of cytotoxic CD8 lymphocytes
has been described to result from the presentation of a
non-conventional tumor antigen in the context of an
undefined non-classical class I molecule [31].
Finally (box 3, escape), extreme HLA-A phenotypes
(HLA-A↑↓)1, very different from those seen in the nor-
mal mucosa, and initially suppressed during the elimina-
tion phase, may (re)appear. Having forced all the
Figure 3 Immunohistochemical staining for CD8 and NKG2A. Two consecutive sections of a colorectal carcinoma lesion displaying a
strongly and homogeneously positive (MEM-E/02 score = 3) neoplastic mucosa were stained by mAb 1A5 to CD8 (A and C) and the polyclonal
antibody N-19 to NKG2A (B and D). Different chromogens reveal CD8 and NKG2A cells in a large peritumoral infiltrate. Counterstaining with
Haematoxilin. Magnification 10 × (panel A and B) and 20 × (panel C and D). Scale bar = 100 μm.
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ingly associated with the poorest outcomes regardless of
HLA-E expression, found to be irrelevant in this group.
Thus, we propose a dual outcome model whereby
HLA-E expression, far from being a manifestation of
immune inhibition and escape, represents instead a pre-
requisite for active immunological scrutiny of edited
HLA tumor variants on the one hand, and triggering
immune responses on the other.
Recently, Levy et al. reported poor MEM-E/02 reactivity
in most colorectal carcinomas, and an association between
high HLA-E expression, detected in just 8 lesions, and
poor prognosis [32]. Poor reactivity is difficult to reconcile
with the high levels of HLA-E detected by us with the
same MEM-E/02 antibody in most lesions, and the prog-
nostic associations proposed by Levy et al. are based on a
limited number of cases. Another example of HLA-E asso-
ciation with poor prognosis is a recent study on early-
stage breast carcinoma [33].
Our results better agree with two cDNA profiling stu-
dies of advanced melanoma in which high levels of
HLA-E transcripts contributed molecular signatures of
favourable prognosis [34,35], and a recent study on glio-
blastoma [36]. Possibly, the balance between activating
and inhibitory functions of HLA-E may differ in differ-
ent tumor histotypes. Additional work is required to
investigate these issues in the context of activation-inhi-
bition models of tumor immune surveillance.
Conclusions
In summary, this is one of the few reports [32,33,37]
addressing the prognostic significance of non-classical
class I molecules in colorectal carcinoma. Additionally, we
provide evidence (albeit indirect) for a functional interplay
between classical and non-classical HLA molecules in
vivo. This is also the first report to suggest in situ engage-
ment of tumor cells and T lymphocytes expressing a
defined ligand:non-rearranging immune receptor pair.
Note added in proof
A tt h et i m eo fp r o o f - e d i t i ng a paper [38] appeared in
PubMed describing a poor prognosis associated with
HLA-E expression in colorectal carcinoma and NKG2A
expression in the lymphoid infiltrate.
Figure 4 Class I HLA expression, immunoediting, and survival through colorectal carcinoma stages. Stepwise selection of HLA
phenotypes results in distinct tumor variants populating the three classical steps (elimination, equilibrium and escape; shaded boxes) of
immunoediting. Equilibrium is defined herein quasi-equilibrium. Unlike ‘true’ equilibrium, that corresponds to occult cancer and dormancy [30],
and was elusive even in experimental models of mouse tumorigenesis [39], quasi-equilibrium refers to edited tumor cells embedded in a
clinically evident tumor mass, sufficiently large to be immunophenotyped in a human pathology facility.
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